Precigen reports Q1 EPS (2c) vs. (18c) last year

Reports Q1 revenue $23.25M, consensus $20.8M. “We are thrilled with the strength of the PAPZIMEOS launch and the pace of revenue growth as we drive broad commercial success across the US and work toward expanded market opportunities in additional geographies and the pediatric patient population,” said Helen Sabzevari, CEO. “Looking ahead, we are excited to advance the next chapter of our AdenoVerse platform through the continued development of PRGN-2009 in HPV-associated cancers, and look forward to sharing more details on our broader pipeline progress later this year.” “We are pleased with the launch performance of PAPZIMEOS, recognizing $21.6M of net revenue in the first full quarter of its launch. In the second quarter of 2026, we are seeing continued strength in revenue growth from PAPZIMEOS,” said CFO Harry Thomasian Jr. “As of March 31, 2026, the Company’s cash, cash equivalents, and investments totaled $56.7M, which based on payment terms, did not include any collection of PAPZIMEOS related accounts receivable since launch of approximately $25.7M. Based on our current revenue outlook and present financial forecast, we continue to believe that our current cash position and anticipated cash to be received from PAPZIMEOS sales will fund operations through cash flow break-even by the end of 2026”.